NeurocrineNeurocrineNeurocrine

Neurocrine

No trades
See on Supercharts

Key facts today


Wedbush raised its target for Neurocrine Biosciences, Inc. (NBIX) to $157, maintaining an 'Outperform' rating. Analysts indicate an average 'buy' rating with a mean target of $168.47.
Analyze the impactAnalyze the impact

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NBIX is featured.